These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 833257)

  • 1. L-Dopa stimulated growth hormone release in the blind.
    Bellastella A; Colucci CF; D'Alessandro B; Lo Cicero M
    J Clin Endocrinol Metab; 1977 Jan; 44(1):194-5. PubMed ID: 833257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blindness impairs plasma growth hormone response to L-dopa but not to arginine.
    Bellastella A; Parlato F; Sinisi AA
    J Clin Endocrinol Metab; 1990 Apr; 70(4):856-8. PubMed ID: 2318945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone inhibitory and stimulatory actions of L-dopa in patients with acromegaly.
    Hanew K; Sasaki A; Sato S; Goh M; Yoshinaga K
    J Clin Endocrinol Metab; 1987 Feb; 64(2):255-60. PubMed ID: 3793848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diminished growth hormone secretion in blind males after L-dopa stimulation.
    Fatranská M; Jurcovicová J; Németh S; Vigas M
    Endocrinol Exp; 1988 Dec; 22(4):243-8. PubMed ID: 3243205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-dopa stimulates release of hypothalamic growth hormone-releasing hormone in humans.
    Chihara K; Kashio Y; Kita T; Okimura Y; Kaji H; Abe H; Fujita T
    J Clin Endocrinol Metab; 1986 Mar; 62(3):466-73. PubMed ID: 3080462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of l-dopa on growth hormone, glucose, insulin, and cortisol response in obese subjects.
    Vizner B; Reiner Z; Sekso M
    Exp Clin Endocrinol; 1983 Jan; 81(1):41-8. PubMed ID: 6343098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression by thyrotropin-releasing hormone (TRH) of human growth hormone release induced by L-dopa.
    Maeda K; Kato Y; Chihara K; Ogo S; Iwasaki Y
    J Clin Endocrinol Metab; 1975 Aug; 41(2):408-11. PubMed ID: 239963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable plasma growth hormone (GH)-releasing hormone and GH responses to clonidine, L-dopa, and insulin in normal men.
    Tapanainen P; Knip M; Lautala P; Leppäluoto J
    J Clin Endocrinol Metab; 1988 Oct; 67(4):845-9. PubMed ID: 3138280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dopamine infusion on plasma levels of growth hormone in normal subjects and in agromegalic patients.
    Verde G; Oppizzi G; Colussi G; Cremascoli G; Botalla L; Müller EE; Silvestrini F; Chiodini PG; Liuzzi A
    Clin Endocrinol (Oxf); 1976 Jul; 5(4):419-23. PubMed ID: 971548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone response to L-dopa in the thinned obese.
    Laurian L; Oberman Z; Hoerer E; Wiznitzer T; Harell A
    Isr J Med Sci; 1982 May; 18(5):625-9. PubMed ID: 7096047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Normalization of the GH response to L-DOPA in acromegalics after treatment with bromocriptine].
    Carmina E; Lanzara P; Lo Coco R; Longo RA; Jannì A
    Arch Sci Med (Torino); 1979; 136(3):421-5. PubMed ID: 549547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of glucose on the growth hormone response to L-dopa in normal and diabetic subjects.
    Ajlouni K; Martinson DR; Hagen TC
    Diabetes; 1975 Jul; 24(7):633-6. PubMed ID: 1158029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men.
    Lal S; Martin JB; De la Vega CE; Friesen HG
    Clin Endocrinol (Oxf); 1975 May; 4(3):277-85. PubMed ID: 1149303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hyperglycemia on the growth hormone response to L-dopa in diabetic subjects.
    Barbarino A; De Marinis L; Martino F
    J Endocrinol Invest; 1978 Jul; 1(3):259-61. PubMed ID: 756876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro effect of dopamine and L-dopa on prolactin and growth hormone release from human pituitary adenomas.
    Peillon F; Cesselin F; Bression D; Zygelman N; Brandi AM; Nousbaum A; Mauborgne A
    J Clin Endocrinol Metab; 1979 Nov; 49(5):737-41. PubMed ID: 489713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Attempt at potentiation of the action of L-dopa on the secretion of growth hormone by benserazide, disulfiram and propranolol].
    Rochiccioli P; Enjaume P; Dutau G; Ribot C; Augier D
    Arch Fr Pediatr; 1976 Jan; 33(1):55-66. PubMed ID: 985031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations of plasma growth hormone (GH)-releasing factor levels during GH stimulation tests in children.
    Donnadieu M; Evain-Brion D; Tonon MC; Vaudry H; Job JC
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1132-4. PubMed ID: 3923020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced growth hormone response to L-dopa and pyridostigmine in obesity.
    Lee EJ; Kim KR; Lee KM; Lim SK; Lee HC; Lee JH; Lee DJ; Huh KB
    Int J Obes Relat Metab Disord; 1994 Jul; 18(7):465-8. PubMed ID: 7920871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine.
    Mims RB; Scott CL; Modebe O; Bethune JE
    J Clin Endocrinol Metab; 1975 Feb; 40(2):256-9. PubMed ID: 1117978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.